Inactive Instrument
NicOx SA Stock Euronext Paris
Stocks
NCOX
FR0000074130
Pharmaceuticals
OTC Markets Traded| Market Cap | 32.96M 37.64M 30.43M 28.41M 53.49M 3.56B 54.71M 366M 141M 1.76B 141M 138M 6.1B | P/E 2026 * |
37.4x | P/E 2027 * | 3.12x |
|---|---|---|---|---|---|
| Enterprise Value | 32.96M 37.64M 30.43M 28.41M 53.49M 3.56B 54.71M 366M 141M 1.76B 141M 138M 6.1B | EV / Sales 2026 * |
3.3x | EV / Sales 2027 * | 1.65x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -7.95% |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Doug Hubatsch
CTO | Chief Tech/Sci/R&D Officer | - | 13/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.95% | -9.39% | - | - | 37.64M | |
| +0.56% | +12.04% | +63.57% | +13.95% | 320B | |
| +0.20% | +8.89% | +33.64% | -3.00% | 72.69B | |
| +2.96% | +11.87% | +47.83% | +122.61% | 9.15B | |
| +0.37% | +3.31% | +4.93% | -2.89% | 8.33B | |
| +9.89% | +6.55% | -0.22% | +11.10% | 4.62B | |
| +11.33% | +10.06% | +11.72% | +35.72% | 3.99B | |
| +11.14% | +0.54% | -28.76% | +34.77% | 3.57B | |
| -0.09% | +5.22% | +50.19% | +56.47% | 2.72B | |
| +7.38% | +11.90% | +17.63% | -21.33% | 2.18B | |
| Average | +3.37% | +8.49% | +22.28% | +27.49% | 47.42B | |
| Weighted average by Cap. | +0.21% | +12.03% | +54.72% | +13.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10M 11.42M 9.23M 8.62M 16.23M 1.08B 16.6M 111M 42.89M 533M 42.89M 41.95M 1.85B | 20M 22.84M 18.46M 17.24M 32.46M 2.16B 33.2M 222M 85.77M 1.07B 85.78M 83.9M 3.7B |
| Net income | 1M 1.14M 923K 862K 1.62M 108M 1.66M 11.11M 4.29M 53.27M 4.29M 4.19M 185M | 11M 12.56M 10.15M 9.48M 17.85M 1.19B 18.26M 122M 47.18M 586M 47.18M 46.14M 2.03B |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
